Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Dr. Jack West recently had the privilege to spend time with Drs Zofia Piotrowska, and Taofeek Owonikoko for a series of case-based discussions.
Dr. Zofia Priotrowska is with the Thoracic Oncology Program at Massachusetts General Hospital Cancer Center in Boston, Massachusetts.
Dr. Taofeek Owonikoko is a Professor with the Department of Hematology and Medical Oncology at Emory University School of Medicine, and Co-Chair of the Clinical and Translational Review Committee at Winship Cancer Institute.
In this series of videos, the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line for a patient with advanced non-squamous non-small cell lung cancer, high PD-L1, and no driver mutation.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…